Centessa Pharmaceuticals (NASDAQ:CNTA) Price Target Raised to $28.00

Centessa Pharmaceuticals (NASDAQ:CNTA) had its target price increased by Guggenheim from $24.00 to $28.00 in a report published on Friday,Benzinga reports. Guggenheim currently has a buy rating on the stock.

Other equities research analysts have also recently issued reports about the stock. Oppenheimer reiterated an “outperform” rating and issued a $14.00 target price on shares of Centessa Pharmaceuticals in a research report on Wednesday, August 14th. BMO Capital Markets raised their target price on shares of Centessa Pharmaceuticals from $20.00 to $35.00 and gave the stock an “outperform” rating in a research note on Monday, September 16th. Morgan Stanley upgraded Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $11.00 to $26.00 in a report on Thursday, September 19th. Jefferies Financial Group increased their price target on Centessa Pharmaceuticals from $13.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, September 11th. Finally, B. Riley began coverage on Centessa Pharmaceuticals in a research note on Thursday, September 19th. They set a “buy” rating and a $33.00 price objective on the stock. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $25.83.

Centessa Pharmaceuticals Price Performance

NASDAQ:CNTA opened at $16.00 on Friday. The stock has a 50 day moving average of $15.90 and a two-hundred day moving average of $12.16. Centessa Pharmaceuticals has a 12 month low of $5.58 and a 12 month high of $18.74. The firm has a market cap of $1.81 billion, a P/E ratio of -10.46 and a beta of 1.47. The company has a current ratio of 21.52, a quick ratio of 13.29 and a debt-to-equity ratio of 0.15.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.05. On average, analysts expect that Centessa Pharmaceuticals will post -1.62 earnings per share for the current fiscal year.

Insider Transactions at Centessa Pharmaceuticals

In related news, CEO Saurabh Saha sold 175,000 shares of the business’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $16.52, for a total value of $2,891,000.00. Following the sale, the chief executive officer now directly owns 776,924 shares in the company, valued at approximately $12,834,784.48. The trade was a 18.38 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Gregory M. Weinhoff sold 12,198 shares of the company’s stock in a transaction dated Thursday, August 22nd. The shares were sold at an average price of $12.17, for a total transaction of $148,449.66. Following the completion of the transaction, the insider now directly owns 241,171 shares in the company, valued at $2,935,051.07. The trade was a 4.81 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 325,031 shares of company stock worth $5,213,043 in the last 90 days. Insiders own 11.59% of the company’s stock.

Institutional Investors Weigh In On Centessa Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC boosted its position in shares of Centessa Pharmaceuticals by 68.7% during the 3rd quarter. Geode Capital Management LLC now owns 56,597 shares of the company’s stock worth $905,000 after purchasing an additional 23,058 shares during the period. Jane Street Group LLC acquired a new position in Centessa Pharmaceuticals during the third quarter worth $2,834,000. Wellington Management Group LLP purchased a new position in shares of Centessa Pharmaceuticals during the third quarter worth $1,609,000. State Street Corp acquired a new stake in shares of Centessa Pharmaceuticals in the third quarter valued at $777,000. Finally, RTW Investments LP purchased a new stake in shares of Centessa Pharmaceuticals in the 3rd quarter valued at $800,000. 82.01% of the stock is owned by hedge funds and other institutional investors.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.